Delisting risk
aTyr Pharma (ATYR)
Develops efzofitimod and tRNA-synthetase-derived therapies for fibrosis and inflammation.
$0.5000
Pre-market+0.00 (+0.20%)
At close$0.4990(+4.72%)
Something off on this page? Send us feedback.
Next report
Nov 5, 2026
in 63 days
EPS estimate
−$0.11
Revenue estimate
$2.5M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported−$0.17−$0.22−$0.26−$0.14−$0.11$0.53−$0.11Pending
Estimate−$0.19−$0.18−$0.20−$0.18−$0.16−$0.15−$0.12−$0.11
Surprise+10.5%−22.2%−30.0%+22.2%+31.3%+453.3%+9.4%—
RevenueReportedEstimate
May '25Aug '25Nov '25Mar '26May '26Aug '26Aug '26Nov '26
Reported——$190.0K——$189.6M$189.6MPending
Estimate——$20.0K$40.0K———$2.5M
Surprise——+850.0%—————
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.11 | — | — |
| Aug 2026 | −$0.12 | −$0.11 | +9.4% |
| Aug 2026 | −$0.15 | $0.53 | +453.3% |
| May 2026 | −$0.16 | −$0.11 | +31.3% |
| Mar 2026 | −$0.18 | −$0.14 | +22.2% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Nov 2025 | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Dec 2022 | |||
| Sep 2022 | |||
| Jun 2022 | |||
| Mar 2022 | |||
| Dec 2021 | |||
| Sep 2021 | |||
| Jun 2021 | |||
| Mar 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 | |||
| Dec 2019 | |||
| Sep 2019 | |||
| Jun 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Dec 2017 | |||
| Sep 2017 | |||
| Jun 2017 | |||
| Mar 2017 | |||
| Dec 2016 | |||
| Sep 2016 | |||
| Jun 2016 | |||
| Mar 2016 | |||
| Dec 2015 | |||
| Sep 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.11 | — | — | $2.5M | — | — | — |
| Aug 7, 2026 | −$0.12 | −$0.11 | +9.4% | — | $189.6M | — | +3.4% |
| Aug 6, 2026 | −$0.15 | $0.53 | +453.3% | — | $189.6M | — | +1.9% |
| May 15, 2026 | −$0.16 | −$0.11 | +31.3% | — | — | — | +3.1% |
| Mar 5, 2026 | −$0.18 | −$0.14 | +22.2% | $40.0K | — | — | −8.7% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||||||
| Nov 6, 2025 | |||||||
| Aug 7, 2025 | |||||||
| May 7, 2025 | |||||||
| Mar 13, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 13, 2024 | |||||||
| May 2, 2024 | |||||||
| Mar 14, 2024 | |||||||
| Sep 30, 2023 | |||||||
| Jun 30, 2023 | |||||||
| Mar 31, 2023 | |||||||
| Dec 31, 2022 | |||||||
| Sep 29, 2022 | |||||||
| Jun 29, 2022 | |||||||
| Mar 30, 2022 | |||||||
| Dec 30, 2021 | |||||||
| Sep 29, 2021 | |||||||
| Jun 30, 2021 | |||||||
| Mar 31, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Sep 30, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Mar 31, 2020 | |||||||
| Dec 31, 2019 | |||||||
| Sep 30, 2019 | |||||||
| Jun 30, 2019 | |||||||
| Mar 31, 2019 | |||||||
| Dec 31, 2018 | |||||||
| Sep 30, 2018 | |||||||
| Jun 30, 2018 | |||||||
| Mar 31, 2018 | |||||||
| Dec 31, 2017 | |||||||
| Sep 30, 2017 | |||||||
| Jun 30, 2017 | |||||||
| Mar 31, 2017 | |||||||
| Dec 31, 2016 | |||||||
| Sep 30, 2016 | |||||||
| Jun 30, 2016 | |||||||
| Mar 31, 2016 | |||||||
| Dec 31, 2015 | |||||||
| Sep 30, 2015 | |||||||